NEWS RELEASE

NEWS
MiCAN will exhibit our booth at the 5th Annual Meeting of the Japanese Society for Regenerative Medicine
2023.03.13
We will introduce research-use blood cells and commissioned evaluations related to immunological and safety assessments of pharmaceuticals, cosmetics, functional foods, and more. We welcome those attending the meeting to visit our booth.
Exhibition:
Booth number 11, Mycan Technologies Co., Ltd.
Date:
March 23-25, 2023
Venue:
National Kyoto International Conference Center Event Hall (Annex)
422 Iwakura-Ookuracho, Sakyo-ku, Kyoto 606-0001, Japan
We will present our seeds at the 5th Regenerative Medicine Industry-Academia Collaboration Techno-Auction.
2023.03.09
We will be presenting details about a new fever-inducing substance test product that uses our company's Mylc cells at the Regenerative Medicine Industry-Academia Collaboration Techno Auction. Those who are attending the Regenerative Medicine Conference are invited to stop by our presentation.
Title: TA-13 Development of a new fever-inducing substance testing product (MylcMAT product) using immortalized myeloid cells (Mylc cells)
Speaker: Kazuo Miyazaki (MyCan Technologies Co., Ltd.)
Date:
March 23, 2023 (Thursday) 16:50-18:50
Venue:
National Kyoto International Conference Center, 1F Room D (Fifth venue)
(422 Iwakura Otsuji-cho, Sakyo-ku, Kyoto-shi, Kyoto 606-0001, Japan)
Our company Miyazaki is scheduled to speak at the Blockbuster TOKYO Lifescience Startup career fair 2023.
2023.03.07
We will be presenting at the Blockbuster TOKYO Lifescience Startup career fair 2023, which is a career fair for life science startups. The event focuses on "talent" as a key factor in the success of startups and provides an opportunity for individuals who are considering a career in startups or are interested in transitioning to a startup to learn more about the industry.
In recent years, the number of people pursuing careers in startups has increased rapidly, in line with the growth of the startup industry. The demand for researchers, management personnel, doctorate degree holders, and back-office staff with immediate practical skills is also rising in the life science startup industry.
This event is for individuals who are interested in transitioning to a life science or healthcare startup or seeking employment opportunities in such startups. If you are considering a career in life science, I would be happy to speak with you. Please feel free to join us at the event!
Date:
Saturday, March 18, 2023, 13:00-18:00 (doors open at 12:30)
Venue:
Tokyo Midtown Yaesu Conference Hall
(4th floor, Tokyo Midtown Yaesu, 2-1 Yaesu 2-chome, Chuo-ku, Tokyo)
Our research on antibody-dependent enhancement of infection using cMylc cells has been published in "Scientific Reports".
2022.09.21
We have conducted a joint research project using immortalized myeloid lineage cells 【cMylc (coronavirus optimized myeloid lineage) cells】generated from iPS cells for research on novel coronavirus (SARS-CoV-2) with the Research Institute for Microbial Diseases, Osaka University. The study on antibody-dependent enhancement of infection (ADE) using cMylc cells, anti-SARS-CoV-2 therapeutic antibodies and sera after mRNA-vaccination has been published in the British online scientific journal Scientific Reports on September 16, 2022 (Japan Standard Time).
BIONNALE 2022に参加します(2022年5月11〜12日開催)
MiCAN participates the BIONNALE (2022.5.11-12)
2022.05.10
BIONNALE 2022に参加し、5月12日 12:00~18:00 (現地時間表記) の「Cooperation | Venture Track」にて弊社の技術・細胞製品紹介をいたします。
We will participate in BIONNALE 2022 and introduce our technology and cell products at "Cooperation | Venture Track" from 12:00 to 18:00 (local time notation) on May 12th.
JITMM Virtual 2020で新型コロナウイルス研究用細胞(cMylc細胞)について紹介します。(2020年12月15~16日開催)
MiCAN will report about cMylc cell for SARS-CoV-2 research in JITMM 2020.
2020.12.13
タイ及びVirtualで行われる熱帯病国際学会(JITMM Virtual 2020)において、新型コロナウイルス研究用細胞cMylc細胞の紹介をします。
MiCAN will report about recent data using cMylc cell for SARS-CoV-2 research in JITMM Virtual 2020 at 15th on Dec.
Infectious Diseases Virtual Partneringに参加します(2020年12月2〜4日開催)
MiCAN participates the Infectious Diseases Virtual Partnering (2020.12.2-4)
2020.12.01
Infectious Diseases Virtual PartneringではMylc, cMylcの感染症用途を中心に紹介します。
At the Infectious Diseases Virtual Partnering, Mylc and cMylc are introduced as a excellent tools of infectious research .
当社初の論文として、「iPS細胞由来ミエロイド系細胞(iMylc)を活用したデングウイルス感受性に関する研究」が専門誌に掲載されました
Our first paper on "Dengue virus susceptibility in novel immortalized myeloid cells" was published in a scientific journal.
2020.11.03
当社は、第67回日本ウイルス学会総会で発表した内容を「iPS細胞由来ミエロイド系細胞(iMylc)を活用したデングウイルス感受性に関する研究」としてまとめました。iPS細胞由来の新規ミエロイド系細胞(当社ではiMylc細胞として、昨年より発売開始中)を用いた、デングウイルスに関する研究です。論文中では、宿主細胞として抗体依存性感染増強(ADE)を検出する細胞としての適応について検討・報告しています。
MiCAN summarized our presentation at the 67th Annual Meeting of the Virological Society of Japan as "Dengue virus susceptibility in novel immortalized myeloid cells". In the paper, we discuss and report on its adaptation as a host cell and detect antibody-dependent warfare infection enhancement (ADE) of Dengue virus research.
新事業拠点・神戸ラボ開設のお知らせ(神戸産業医療都市、クリエイティブラボ神戸/CLIK)
Notice of New R&D Laboratory Opening (at the KOBE Biomedical Innovation Cluster, Creative Lab for Innovation in Kobe/CLIK)
2020.11.02
当社は、自社で開発したiPS細胞由来ミエロイド系細胞 (Mylc) を利用した研究用検査キット開発のため、神戸産業医療都市に新事業拠点を設置しました(設置場所:神戸ポートアイランド、クリエイティブラボ/CLIK)
New R&D laboratory is opening at KOBE Biomedical Innovation Cluster to develop some research evaluation kits using our myeloidal cells, Mylc. (Place: Kobe Port-Island, Creative lab for innovation in KOBE).
新型コロナウイルス研究用細胞cMylc提供開始のお知らせ
Providing an ideal human blood cell, Mylc, for novel coronavirus COVID-19 research
2020.10.09
当社は、自社で開発したiPS細胞由来ミエロイド系細胞 (Mylc) を新型コロナウイルス研究用に改変した【cMylc細胞】を作製し2020年10月9日よりキット提供(*)を開始しました。コロナウイルス宿主として世界初のヒト血球系免疫細胞であり、既存細胞(サル腎臓由来Vero細胞)と同等の感染を示します。(*)アカデミア研究用には12月頃まで無償提供
On October 9, 2020, we will provide cMylc cells for the novel coronavirus research. cMylc cells, derived from iPS cells (Mylc) that we developed in-house, are the host cells of novel coronavirus as the first human blood cells. The viral infection and proliferation effects are comparable to those of Vero cells(Monkey kidney derived).
新製品の販売開始のお知らせ
New Product Release
2020.09.09
当社は、自社で開発したiPS細胞由来ミエロイド系細胞 (Mylc) を使⽤した、食品・化粧品等に関わる機能性材料の安全性等のサイトカイン評価キット【Mylc ELISA (Human IL-6) Kit】の提供を2020年9月9日より開始します。
On September 9, 2020, we will release the Mylc ELISA (Human IL-6) Kit, a kit for the evaluation of cytokines for the safety of functional materials related to food and cosmetics, etc., using myeloid cells derived from iPS cells (Mylc) that we developed in-house.
ChinaBio Partnering Forum 2020に出展します
2020.08.19
当社はJETROの支援プログラムを活用し、来週8月25日〜27日にWebで開催されるChinaBio Partnering Forum 2020に出展します。弊社の細胞製品紹介および提供先・協業先の発掘を行う予定です。
MiCAN will be exhibiting at the ChinaBio Partnering Forum 2020, which will be held next week on the web from August 25 to 27 with the help of JETRO's support program.
Joint international tropical medicine meeting Virtual 2020に出展します
2020.08.16
当社は、本年12月15日〜16日にWebで開催されるJoint internatonal tropical medine meeting (JITMM: 例年はタイ・バンコクで開催)に、スポンサーとして出展します。スポンサー枠講演で、弊社の未成熟樹状細胞(Mylc)製品などを使用した新型コロナウイルス感染症等に関する最新の研究成果を先生方に発表いただく予定です。
MiCAN, as a sponsor, will participate in the Joint international tropical medicine meeting (JITMM: usually held in Bangkok, Thailand) to be held on December 15-16, 2020. In the sponsorship session, we will have presentations on the latest research results on novel coronavirus infections using our immature dendritic cells (Mylc) and other products.